Clinical Trial Update: Lot-to-lot Consistency Study of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants From 2 Months of Age [Phase 3]

View source ↗

Summary

Phase 3 trial update evaluating lot-to-lot consistency of a 21-valent pneumococcal conjugate vaccine in healthy infants starting at 2 months of age.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pneumococcal Disease

Drugs mentioned

• 21-valent pneumococcal conjugate vaccine (Pneumococcal conjugate vaccine, 21-valent)

Snippet

Sponsor: Sanofi | Conditions: Pneumococcal Immunization, Healthy Volunteers | Phase 3 | Status: RECRUITING